Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ochratoxin A from a toxicological perspective.

E Petzinger1, K Ziegler

  • 1Justus-Liebig-University, Institute of Pharmacology and Toxicology, Frankfurter Str. 107, D-35392 Giessen, Germany. ernst.petzinger@vetmed.uni-giessen.de

Journal of Veterinary Pharmacology and Therapeutics
|June 10, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Short Note on the Density of States in 3D Weyl Semimetals.

Physical review letters·2018
Same author

Myeloid protein tyrosine phosphatase 1B (PTP1B) deficiency protects against atherosclerotic plaque formation in the ApoE<sup>-/-</sup> mouse model of atherosclerosis with alterations in IL10/AMPKα pathway.

Molecular metabolism·2017
Same author

EIectrical impedance and transepidermal water loss of healthy human skin under different conditions.

Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)·2016
Same author

Superior functional outcome after femoral derotation osteotomy according to gait analysis in cerebral palsy.

Gait & posture·2014
Same author

Transport of the placental estriol precursor 16α-hydroxy-dehydroepiandrosterone sulfate (16α-OH-DHEAS) by stably transfected OAT4-, SOAT-, and NTCP-HEK293 cells.

The Journal of steroid biochemistry and molecular biology·2014
Same author

In vitro induction of tumor necrosis factor-α by ochratoxin A (OTA) from rat liver: role of Kupffer cells.

Mycotoxin research·2013
Same journal

Different Roles of Canine Cytochrome P450 2C and 3A Enzymes Involved in the Oxidative Metabolism of Phenobarbital, a Key Anticonvulsant for Dogs: Comparison With Human P450 Enzymes.

Journal of veterinary pharmacology and therapeutics·2026
Same journal

What Do We Know About Cyclooxygenases Expression in the Lower Urinary Tract of Dogs and Cats? A Systematic Review.

Journal of veterinary pharmacology and therapeutics·2026
Same journal

Pharmacokinetics of Orally Administered Clonidine in Dogs.

Journal of veterinary pharmacology and therapeutics·2026
Same journal

Veterinary Pharmaceutical Safety Competencies for New Graduates: Description of an Interprofessional Simulated Learning Activity.

Journal of veterinary pharmacology and therapeutics·2026
Same journal

Characterization of the Pharmacokinetics and Physiological Effects of Tapentadol in Horses.

Journal of veterinary pharmacology and therapeutics·2026
Same journal

A Visual Analogue Scale Exercise for Teaching Antimicrobial Selection in Veterinary Pharmacology: Tool Development and Initial Implementation.

Journal of veterinary pharmacology and therapeutics·2026
See all related articles

Ochratoxin A (OTA), a common food contaminant, persists in humans and can cause kidney damage and cancer. This study suggests a lower acceptable daily intake and maximum residue level for OTA in foods.

Area of Science:

  • Food safety
  • Toxicology
  • Mycotoxicology

Background:

  • Ochratoxin A (OTA) is a prevalent mycotoxin from Aspergillus and Penicillium molds.
  • Found in cereals, plant products, and pork due to contaminated feed.
  • OTA exhibits long persistence in humans, with a 35-day half-life, leading to frequent detection in blood.

Purpose of the Study:

  • To evaluate the toxicological risks associated with Ochratoxin A exposure.
  • To propose revised acceptable daily intake (ADI) and maximum residue levels (MRLs) for OTA.

Main Methods:

  • Review of toxicological data on OTA, including carcinogenicity, nephrotoxicity, teratogenesis, and immunotoxicity.
  • Analysis of OTA's pharmacokinetic and toxicokinetic properties in humans.
  • Evaluation of current and proposed regulatory limits for OTA in foodstuffs.

Related Experiment Videos

Main Results:

  • OTA is classified as a possible human carcinogen (Group 2B) and is a potent carcinogen in rodents.
  • Demonstrates significant nephrotoxicity, teratogenesis, and immunotoxicity.
  • Current proposed EU MRL of 5 µg/kg for cereals may not be sufficiently protective.

Conclusions:

  • An acceptable daily intake (ADI) of 1.5 ng OTA/kg body weight is proposed.
  • A significantly lower maximum residue level (MRL) than the currently postulated 5 µg/kg for cereals is recommended.
  • Stricter regulatory limits are necessary to mitigate the health risks posed by Ochratoxin A contamination.